CD44 and osteosarcoma: Our analysis of the reversal effect of anlotinib in vitro and in vivo indicates that anlotinib may be adopted as a novel chemosensitizer to overcome MDR in patients with osteosarcoma or other types of tumors that overexpress PGP1.